New scan could predict which breast cancer patients will respond to hormone therapy
NCT ID NCT02398773
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 36 times
Summary
This study is testing whether a special PET scan called FES PET/CT can predict how well hormone therapy will work for people with newly diagnosed breast cancer that has spread. The scan uses a radioactive form of estrogen to light up cancer cells that respond to hormones. About 99 participants will get the scan before starting treatment, and doctors will check if the scan results match how the cancer responds after 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV BREAST CANCER AJCC V6 AND V7 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Comprehensive Cancer Center
Duarte, California, 91010, United States
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Fox Chase Cancer Center - East Norriton Hospital Outpatient Center
East Norriton, Pennsylvania, 19401, United States
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
ProHealth D N Greenwald Center
Mukwonago, Wisconsin, 53149, United States
-
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066, United States
-
ProHealth Waukesha Memorial Hospital
Waukesha, Wisconsin, 53188, United States
-
Sidney and Lois Eskenazi Hospital
Indianapolis, Indiana, 46202, United States
-
Springmill Medical Center
Indianapolis, Indiana, 46290, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
UW Cancer Center at ProHealth Care
Waukesha, Wisconsin, 53188, United States
-
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
University of Washington Medical Center - Montlake
Seattle, Washington, 98195, United States
-
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792, United States
-
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, 37232, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.